
-
11/19/2020
PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA
-
07/20/2020
PAION AG: YICHANG HUMANWELL RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN CHINA
-
07/02/2020
PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVO) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
-
03/12/2020
PAION AG: COSMO ANNOUNCES BRIEF EXTENSION OF FDA REVIEW PERIOD FOR NDA FOR REMIMAZOLAM
-
01/23/2020
PAION AG: MUNDIPHARMA RECEIVES MARKET APPROVAL FOR ANEREM(R) (REMIMAZOLAM) IN GENERAL ANESTHESIA IN JAPAN
-
01/08/2020
PAION GRANTS REMIMAZOLAM LICENSE FOR SOUTHEAST ASIA TO HANA PHARM